Kinetin has been shown to be one of the most potent drugs to correct IKBKAP alternative splicing and upregulate IKAP expression in FD cells [25, 26] although its therapeutic potential is uncertain due to possible side effects and toxicity in FD patients [60]. Here, ELP1 is linked to Fabry disease.